Elsevier

Immunology Letters

Volume 92, Issue 3, 15 April 2004, Pages 199-205
Immunology Letters

Review
Fc γ receptors

https://doi.org/10.1016/j.imlet.2004.01.012Get rights and content

Section snippets

How Fcγ receptors bind IgG

The Fc region is separated from the antigen binding parts of the IgG molecule by a flexible hinge region and forms two structural domains, the CH2 and CH3 domains. Cellular and structural approaches have shown that the lower hinge region contains the major binding site for FcγR. It is established that cross-linking of FcγR membrane molecules is a prerequisite to IgG-mediated cell activation. Since the Fc portion is composed of two identical polypeptide chains which are related to each other by

Roles of Fcγ receptors in autoimmunity

Mice deleted for the ITAM-bearing signal-transducing γ chain associated to FcγRI and FcγRIII or for their respective ligand binding chains have impaired in vitro IgG-dependent phagocytic and ADCC responses (Table 2) [20], [21], [22]. Since the γ chain is associated to the high affinity receptor for IgE, the γ-chain deficient mast cells are unable to respond not only to IgG but also to IgE. These mice are unable to mount type I and type III hypersensitivity reactions and are resistant to the

Roles of Fcγ receptors in antibody-based therapies

There has been a renewed interest since few years in the use of mAbs in the diagnostic and treatment of various tumors [33] (Table 4).The most impressive clinical results have been obtained with Rituximab, a chimeric anti-CD20 mAb in the treatment of B cell lymphoma [34]. A humanized mAb that recognizes the human oncoprotein HER-2/neu over-expressed in some breast cancers and other tumors, induces clinical responses [35]. Other mAbs such as Campath-1H or 17-1A produced encouraging results in

Ectopic expression of FcγR on non-hematopoı̈etic tumor cells

The first studies indicating that non-hematopoı̈etic tumors may express FcRs were performed on a variety of experimental tumors [45] and of human cancers [46], [47]. However, the ectopic expression of FcγRs by non-hematopoı̈etic tumor cells was a controversy because of the presence of FcγR positive inflammatory cells at the tumor site [48] and because FcγR expression was lost during short-term culture of tumor cells in vitro [49]. We reinvestigated the expression of FcγRs on human

Conclusion

The knowledge on FcγR functions and structure has indeed progressed a lot since their original discovery by the 70′ s [52], [53], [54], [55]. FcγR are important molecules not only to mediate and control the effectors functions of IgG antibodies, but they also control the autoimmunity-tolerance balance in the periphery. Furthermore, they are major actors of the efficacy of therapeutic antibodies. The recent description of the crystal structure of the FcγR/Fc complex opens new possibilities to

First page preview

First page preview
Click to open first page preview

References (55)

  • H.R. Koene et al.

    FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype

    Blood

    (1997)
  • M.M. Goldenberg

    Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

    Clin. Ther.

    (1999)
  • G. Cartron et al.

    Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIA gene

    Blood

    (2002)
  • A.B. Van Spriel et al.

    Immunotherapeutic perspective for bispecific antibodies

    Immunol. Today

    (2000)
  • P. Bruhns et al.

    Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

    Immunity

    (2003)
  • I.P. Witz

    Tumor-bound immunoglobulins: in situ expressions of humoral immunity

    Adv. Cancer Res.

    (1977)
  • W.H. Fridman et al.

    Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells)

    Cell Immunol.

    (1974)
  • J. Ravetch et al.

    IgG Fc receptors

    Annu. Rev. Immunol.

    (2001)
  • M. Reth

    Antigen receptor tail clue

    Nature

    (1989)
  • I.E. Van den Herik-Oudijk et al.

    Identification of signaling motifs within human FcγRIIa and FcγRIIb isoforms

    Blood

    (1995)
  • S. Amigorena et al.

    Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes

    Science.

    (1992)
  • M. Daeron

    Fc receptor biology

    Annu. Rev. Immunol.

    (1997)
  • L. Pricop et al.

    Differential modulation of stimulatory and inhibitory FcγR on human monocytes by Th1 and Th2 cytokines

    J. Immunol.

    (2001)
  • L.L. Lanier et al.

    Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid

    Science

    (1989)
  • J.E. Salmon et al.

    FcγRIII on human neutrophils. Allelic variants have functionally distinct capacities

    J Clin Invest.

    (1990)
  • P. Boros et al.

    IgM anti-FcγR autoantibodies trigger neutrophil degranulation

    J. Exp. Med.

    (1991)
  • J. Galon et al.

    Soluble FcγR (FcγRIII, CD16) triggers cell activation through interaction with complement receptors

    J. Immunol.

    (1996)
  • Cited by (78)

    • Evaluation of Hydrogen Exchange Mass Spectrometry as a Stability-Indicating Method for Formulation Excipient Screening for an IgG4 Monoclonal Antibody

      2018, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      The higher order structure of a mAb consists of 2 antigen-binding domains (Fab) and 1 crystalizable domain (Fc). These structural elements are arranged in a “Y-shaped” structure, with the linkages between domains being highly flexible.6-8 Owing to the flexible linker, mAbs are highly dynamic molecules in solution, capable of movements ranging from small-scale fluctuations to large-scale rearrangements of the domains.7-9

    • How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma

      2017, Blood Reviews
      Citation Excerpt :

      There is evidence for the existence of 3 FcgR classes (I, II, and III) and 8 subclasses, being haplotype distribution markedly different among various ethnic groups [41] (Fig. 2). Polymorphisms in FcgR genes have been reported to be able to influence efficacy of antibody-based therapies [40]. Fc-gamma RII-a (CD32a) and Fc-gamma RIII-a (CD16A) have been shown capable to activate effector cells, while Fc-gamma RII-b (CD32B) is reported to inhibit their activation.

    View all citing articles on Scopus
    View full text